NCT05132075 - Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

March 30, 2026

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

JDQ443

JDQ443 tablets, orally administered

DRUG

docetaxel

docetaxel concentrated solution for infusion, intravenously administered

Trial Locations (53)

1000

Novartis Investigative Site, Ljubljana

1121

Novartis Investigative Site, Budapest

4066

Novartis Investigative Site, Auchenflower

4101

Novartis Investigative Site, South Brisbane

6800

Novartis Investigative Site, Ankara

10330

Novartis Investigative Site, Bangkok

11526

Novartis Investigative Site, Athens

11941

Novartis Investigative Site, Amman

13620

Novartis Investigative Site, Seongnam-si

14004

Novartis Investigative Site, Córdoba

28009

Novartis Investigative Site, Madrid

31008

Novartis Investigative Site, Pamplona

33011

Novartis Investigative Site, Oviedo

33081

Novartis Investigative Site, Aviano

34093

Novartis Investigative Site, Istanbul

34899

Novartis Investigative Site, Istanbul

55100

Novartis Investigative Site, Lucca

59100

Novartis Investigative Site, Kuala Lumpur

70403

Novartis Investigative Site, Tainan City

90375

Novartis Investigative Site, Ed Daoura

93586

Novartis Investigative Site, Kuching

98055

Valley Medical Center Research, Renton

100730

Novartis Investigative Site, Beijing

110042

Novartis Investigative Site, Shengyang

110085

Novartis Investigative Site, Delhi

150081

Novartis Investigative Site, Harbin

250117

Novartis Investigative Site, Jinan

300000

Novartis Investigative Site, Hanoi

302019

Novartis Investigative Site, Jaipur

310003

Novartis Investigative Site, Hangzhou

350014

Novartis Investigative Site, Fuzhou

400042

Novartis Investigative Site, Chongqing

400124

Novartis Investigative Site, Cluj-Napoca

410013

Novartis Investigative Site, Changsha

510080

Novartis Investigative Site, Guangzhou

999077

Novartis Investigative Site, Hong Kong

999999

Novartis Investigative Site, Kowloon

C1414DRK

Novartis Investigative Site, CABA

B1629AHJ

Novartis Investigative Site, Pilar

H4A 3J1

Novartis Investigative Site, Montreal

J1H 5N4

Novartis Investigative Site, Sherbrooke

FI-20521

Novartis Investigative Site, Turku

115 27

Novartis Investigative Site, Athens

715 00

Novartis Investigative Site, Heraklion Crete

Unknown

Novartis Investigative Site, Kowloon

IS-101

Novartis Investigative Site, Reykjavik

00128

Novartis Investigative Site, Roma

06760

Novartis Investigative Site, Mexico City

4454-513

Novartis Investigative Site, Matosinhos Municipality

4100-180

Novartis Investigative Site, Porto

01140

Novartis Investigative Site, Adana

06500

Novartis Investigative Site, Ankara

06680

Novartis Investigative Site, Ankara